Physical Address

304 North Cardinal St.
Dorchester Center, MA 02124

Naltrexone

Naltrexone is a medication that is primarily used to treat alcohol and opioid dependence. It belongs to a class of drugs called opioid antagonists. Here is some information about naltrexone:

NALTREXONE

Treatment of Alcohol and Opioid Dependence

Naltrexone is commonly prescribed as part of a comprehensive treatment program for individuals who are dependent on alcohol or opioids. It works by blocking the effects of opioids in the brain and reducing the desire to drink alcohol. Naltrexone is not a cure for addiction, but it can be an effective tool in managing cravings and preventing relapse.

Mechanism of Action

Naltrexone works by blocking the opioid receptors in the brain, which are responsible for the pleasurable effects of alcohol and opioids. By blocking these receptors, naltrexone reduces the rewarding effects of these substances, making it less desirable to use them. It can help individuals maintain abstinence and decrease the likelihood of relapse.

Forms of Naltrexone

Naltrexone is available in different forms, including oral tablets and a long-acting injectable formulation. The oral tablets are usually taken once daily, while the injectable form is administered once a month. The choice of formulation depends on individual needs and preferences, as well as the recommendations of a healthcare professional.

Precautions and Potential Side Effects

Naltrexone may cause certain side effects, although they are generally mild and well-tolerated. Common side effects may include nausea, headache, dizziness, fatigue, and gastrointestinal upset. In rare cases, naltrexone can cause liver problems, so regular monitoring of liver function is recommended during treatment.

It is important to note that naltrexone should not be used in individuals who are still using opioids or alcohol, as it can precipitate withdrawal symptoms. It is important to have a period of abstinence before starting naltrexone treatment.

Consultation with Healthcare Professional

Naltrexone is a prescription medication, and its use should be supervised by a healthcare professional, such as a doctor or addiction specialist. It is important to consult with a healthcare professional to determine the appropriate dosage, discuss potential risks and benefits, and develop a comprehensive treatment plan for alcohol or opioid dependence.

WARNING: Please consult with a healthcare professional or doctor for personalized advice and guidance regarding the use of naltrexone or any other medication for the treatment of alcohol or opioid dependence. They will be able to provide specific instructions based on your medical history and individual needs.

References

  1. ^ Jump up to:a b c d e f g h i j k l m n o “Revia (naltrexone hydrochloride tablets USP50 mgOpioid Antagonist”. DailyMed. 24 April 2015. Archived from the original on 14 June 2022. Retrieved 13 June 2022.
  2. ^ Jump up to:a b c “Contrave Extended-Release – naltrexone hydrochloride and bupropion hydrochloride tablet, extended release”. DailyMed. 4 November 2021. Archived from the original on 4 June 2020. Retrieved 13 June 2022.
  3. ^ Jump up to:a b c d “Vivitrol- naltrexone kit”. DailyMed. 10 March 2021. Archived from the original on 30 May 2022. Retrieved 13 June 2022.
  4. ^ Jump up to:a b c d e f g h i j k l m n o p q r s t u v w x y Gonzalez JP, Brogden RN (March 1988). “Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence”. Drugs. 35 (3): 192–213. doi:10.2165/00003495-198835030-00002. PMID 2836152.
  5. ^ Jump up to:a b c d Lee MW, Fujioka K (August 2009). “Naltrexone for the treatment of obesity: review and update”. Expert Opinion on Pharmacotherapy. 10 (11): 1841–1845. CiteSeerX 10.1.1.496.9477. doi:10.1517/14656560903048959. PMID 19537999. S2CID 207477935.
  6. ^ Jump up to:a b c d e f g h i j k l m “Naltrexone Monograph for Professionals – Drugs.com”. Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 9 November 2017. Retrieved 9 November 2017.
  7. ^ Jump up to:a b c d e f g Colasanti A, Lingford-Hughes A, Nutt D (2013). “Opioids Neuroimaging”. In Miller PM (ed.). Biological Research on Addiction. Comprehensive Addictive Behaviors and Disorders. Vol. 2. Elsevier. pp. 675–687. doi:10.1016/B978-0-12-398335-0.00066-2. ISBN 9780123983350.
  8. ^ Jump up to:a b c d e f g h Lee MC, Wagner HN, Tanada S, Frost JJ, Bice AN, Dannals RF (July 1988). “Duration of occupancy of opiate receptors by naltrexone”. Journal of Nuclear Medicine. 29 (7): 1207–1211. PMID 2839637. Archived from the original on 29 October 2021. Retrieved 29 October 2021.
  9. ^ Jump up to:a b c Sevarino KA, Kosten TR (2009). “Naltrexone for Initiation and Maintenance of Opiate Abstinence”. In Dean RL, Bilsky EJ, Negus SS (eds.). Opiate Receptors and Antagonists. Humana Press. pp. 227–245. doi:10.1007/978-1-59745-197-0_12. ISBN 978-1-58829-881-2.
  10. ^ Jump up to:a b c Aboujaoude E, Salame WO (August 2016). “Naltrexone: A Pan-Addiction Treatment?”. CNS Drugs. 30 (8): 719–733. doi:10.1007/s40263-016-0373-0. PMID 27401883. S2CID 6372144.
  11. ^ Tran TH, Griffin BL, Stone RH, Vest KM, Todd TJ (July 2017). “Methadone, Buprenorphine, and Naltrexone for the Treatment of Opioid Use Disorder in Pregnant Women”. Pharmacotherapy. 37 (7): 824–839. doi:10.1002/phar.1958. PMID 28543191. S2CID 13772333.
  12. ^ Jump up to:a b c Sadock BJ, Sadock VA, Sussman N (2012). Kaplan & Sadock’s Pocket Handbook of Psychiatric Drug Treatment. Lippincott Williams & Wilkins. p. 265. ISBN 9781451154467. Archived from the original on 5 December 2017.
  13. ^ “Naltrexone/bupropion for obesity”. Drug and Therapeutics Bulletin. 55 (11): 126–129. November 2017. doi:10.1136/dtb.2017.11.0550. PMID 29117992. S2CID 547660.
  14. ^ Jump up to:a b Spencer CN, Elton A, Dove S, Faulkner ML, Robinson DL, Boettiger CA (September 2023). “Naltrexone engages a brain reward network in the presence of reward-predictive distractor stimuli in males”. Addiction Neuroscience. 7: 100085. doi:10.1016/j.addicn.2023.100085. ISSN 2772-3925. S2CID 257919116.
  15. ^ Spanagel R, Weiss F (November 1999). “The dopamine hypothesis of reward: past and current status”. Trends in Neurosciences. 22 (11): 521–527. doi:10.1016/s0166-2236(99)01447-2. PMID 10529820. S2CID 35758115.
  16. ^ Rösner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M (December 2010). Srisurapanont M (ed.). “Opioid antagonists for alcohol dependence”. The Cochrane Database of Systematic Reviews (12): CD001867. doi:10.1002/14651858.CD001867.pub2. PMID 21154349.
  17. ^ Donoghue K, Elzerbi C, Saunders R, Whittington C, Pilling S, Drummond C (June 2015). “The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta-analysis”. Addiction. 110 (6): 920–930. doi:10.1111/add.12875. PMID 25664494. Archived from the original on 15 April 2019. Retrieved 15 April 2019.
  18. ^ Garbutt JC (2010). “Efficacy and tolerability of naltrexone in the management of alcohol dependence”. Current Pharmaceutical Design. 16 (19): 2091–2097. doi:10.2174/138161210791516459. PMID 20482515.
  19. ^ Garbutt JC, Greenblatt AM, West SL, Morgan LC, Kampov-Polevoy A, Jordan HS, Bobashev GV (August 2014). “Clinical and biological moderators of response to naltrexone in alcohol dependence: a systematic review of the evidence”. Addiction. 109 (8): 1274–1284. doi:10.1111/add.12557. PMID 24661324.
  20. ^ Ray LA, Chin PF, Miotto K (March 2010). “Naltrexone for the treatment of alcoholism: clinical findings, mechanisms of action, and pharmacogenetics”. CNS & Neurological Disorders Drug Targets. 9 (1): 13–22. doi:10.2174/187152710790966704. PMID 20201811.
  21. ^ Maisel NC, Blodgett JC, Wilbourne PL, Humphreys K, Finney JW (February 2013). “Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?”. Addiction. 108 (2): 275–293. doi:10.1111/j.1360-0443.2012.04054.x. PMC 3970823. PMID 23075288.
  22. ^ Jump up to:a b Sinclair JD (2001). “Evidence about the use of naltrexone and for different ways of using it in the treatment of alcoholism”. Alcohol and Alcoholism. 36 (1): 2–10. doi:10.1093/alcalc/36.1.2. PMID 11139409.
  23. ^ Jump up to:a b Sharma A, Kelly SM, Mitchell SG, Gryczynski J, O’Grady KE, Schwartz RP (June 2017). “Update on Barriers to Pharmacotherapy for Opioid Use Disorders”. Current Psychiatry Reports. 19 (6): 35. doi:10.1007/s11920-017-0783-9. PMC 7075636. PMID 28526967.
  24. ^ Sharma B, Bruner A, Barnett G, Fishman M (July 2016). “Opioid Use Disorders”. Child and Adolescent Psychiatric Clinics of North America. 25 (3): 473–487. doi:10.1016/j.chc.2016.03.002. PMC 4920977. PMID 27338968.
  25. ^ Jump up to:a b Wakeman SE, Larochelle MR, Ameli O, Chaisson CE, McPheeters JT, Crown WH, et al. (February 2020). “Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder”. JAMA Network Open. 3 (2): e1920622. doi:10.1001/jamanetworkopen.2019.20622. PMID 32022884. S2CID 211035316.
  26. ^ Comer SD, Sullivan MA, Yu E, Rothenberg JL, Kleber HD, Kampman K, et al. (February 2006). “Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial”. Archives of General Psychiatry. 63 (2): 210–218. doi:10.1001/archpsyc.63.2.210. PMC 4200530. PMID 16461865.
  27. ^ Shulman M, Wai JM, Nunes EV (June 2019). “Buprenorphine Treatment for Opioid Use Disorder: An Overview”. CNS Drugs. 33 (6): 567–580. doi:10.1007/s40263-019-00637-z. PMC 6585403. PMID 31062259.
  28. ^ Jump up to:a b Lee JD, Nunes EV, Novo P, Bachrach K, Bailey GL, Bhatt S, et al. (January 2018). “Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial”. Lancet. 391 (10118): 309–318. doi:10.1016/S0140-6736(17)32812-X. PMC 5806119. PMID 29150198.
  29. ^ Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. World Health Organization. 2009. ISBN 978-92-4-154754-3.[page needed]
  30. ^ Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A (April 2011). Minozzi S (ed.). “Oral naltrexone maintenance treatment for opioid dependence”. The Cochrane Database of Systematic Reviews. 2011 (4): CD001333. doi:10.1002/14651858.CD001333.pub4. PMC 7045778. PMID 21491383.
  31. ^ Johansson BA, Berglund M, Lindgren A (April 2006). “Efficacy of maintenance treatment with naltrexone for opioid dependence: a meta-analytical review”. Addiction. 101 (4): 491–503. doi:10.1111/j.1360-0443.2006.01369.x. PMID 16548929.
  32. ^ David SP, Lancaster T, Stead LF, Evins AE, Prochaska JJ (June 2013). “Opioid antagonists for smoking cessation”. The Cochrane Database of Systematic Reviews. 6 (6): CD003086. doi:10.1002/14651858.CD003086.pub3. PMC 4038652. PMID 23744347.
  33. ^ Mouaffak F, Leite C, Hamzaoui S, Benyamina A, Laqueille X, Kebir O (2017). “Naltrexone in the Treatment of Broadly Defined Behavioral Addictions: A Review and Meta-Analysis of Randomized Controlled Trials”. European Addiction Research. 23 (4): 204–210. doi:10.1159/000480539. PMID 28877518.
  34. ^ Ryback RS (July 2004). “Naltrexone in the treatment of adolescent sexual offenders”. The Journal of Clinical Psychiatry. 65 (7): 982–986. doi:10.4088/jcp.v65n0715. PMID 15291688.
  35. ^ “Low dose naltrexone – MEpedia”.
  36. ^ O’Kelly B, Vidal L, McHugh T, Woo J, Avramovic G, Lambert JS (October 2022). “Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study”. Brain, Behavior, & Immunity – Health. 24: 100485. doi:10.1016/j.bbih.2022.100485. PMC 9250701. PMID 35814187.
  37. ^ Jump up to:a b c d Milhorn HT (17 October 2017). Substance Use Disorders: A Guide for the Primary Care Provider. Springer International Publishing. pp. 88–. ISBN 978-3-319-63040-3. Archived from the original on 27 April 2021. Retrieved 4 December 2017.
  38. ^ Jump up to:a b ““Alcoholism Once A Month Injectable Drug, Vivitrol, Approved By FDA”. Medical News Today. 16 April 2006. Archived from the original on 5 January 2009.
  39. ^ Therapeutic Goods Administration. “Australian Register of Therapeutic Goods Medicines” (Online database of approved medicines). Archived from the original on 14 May 2009. Retrieved 22 March 2009.
  40. ^ Therapeutic Goods Administration. “Australian Register of Therapeutic Goods Medicines” (Online database of approved medicines, specific entry for “O’Neil Long Acting Naltrexone Implant”). Retrieved 27 April 2017.[permanent dead link]
  41. ^ Hulse GK, Morris N, Arnold-Reed D, Tait RJ (October 2009). “Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone”. Archives of General Psychiatry. 66 (10): 1108–1115. doi:10.1001/archgenpsychiatry.2009.130. PMID 19805701.
  42. ^ Galanter M, Kleber HD, eds. (2008). The American Psychiatric Publishing Textbook of Substance Abuse Treatment. American Psychiatric. ISBN 978-1-58562-276-4.[page needed]
  43. ^ Jump up to:a b c d e f g h i j Miotto K, McCann M, Basch J, Rawson R, Ling W (2002). “Naltrexone and dysphoria: fact or myth?”. The American Journal on Addictions. 11 (2): 151–160. doi:10.1080/10550490290087929. PMID 12028745.
  44. ^ Jump up to:a b c Strain EC, Stitzer ML (2006). The Treatment of Opioid Dependence. JHU Press. pp. 296–. ISBN 978-0-8018-8219-7. Archived from the original on 2 June 2021. Retrieved 2 June 2021.
  45. ^ Jump up to:a b c d e Nathan PJ, O’Neill BV, Napolitano A, Bullmore ET (October 2011). “Neuropsychiatric adverse effects of centrally acting antiobesity drugs”. CNS Neuroscience & Therapeutics. 17 (5): 490–505. doi:10.1111/j.1755-5949.2010.00172.x. PMC 6493804. PMID 21951371.
  46. ^ Jump up to:a b Krupitsky E, Zvartau E, Blokhina E, Verbitskaya E, Wahlgren V, Tsoy-Podosenin M, et al. (September 2016). “Anhedonia, depression, anxiety, and craving in opiate dependent patients stabilized on oral naltrexone or an extended release naltrexone implant”. The American Journal of Drug and Alcohol Abuse. 42 (5): 614–620. doi:10.1080/00952990.2016.1197231. PMC 5156574. PMID 27436632.
  47. ^ Mendelson JH, Ellingboe J, Keuhnle JC, Mello NK (October 1978). “Effects of naltrexone on mood and neuroendocrine function in normal adult males”. Psychoneuroendocrinology. 3 (3–4): 231–236. doi:10.1016/0306-4530(78)90013-6. PMID 219434. S2CID 7712730.
  48. ^ Hollister LE, Johnson K, Boukhabza D, Gillespie HK (August 1981). “Aversive effects of naltrexone in subjects not dependent on opiates”. Drug and Alcohol Dependence. 8 (1): 37–41. doi:10.1016/0376-8716(81)90084-3. PMID 7297411.
  49. ^ Crowley TJ, Wagner JE, Zerbe G, Macdonald M (September 1985). “Naltrexone-induced dysphoria in former opioid addicts”. The American Journal of Psychiatry. 142 (9): 1081–1084. doi:10.1176/ajp.142.9.1081. PMID 2992300.
  50. ^ Jump up to:a b c Malcolm R, O’Neil PM, Von JM, Dickerson PC (June 1987). “Naltrexone and dysphoria: a double-blind placebo controlled trial”. Biological Psychiatry. 22 (6): 710–716. doi:10.1016/0006-3223(87)90202-2. PMID 3593812. S2CID 39628172.
  51. ^ Pettinati HM, O’Brien CP, Rabinowitz AR, Wortman SP, Oslin DW, Kampman KM, Dackis CA (December 2006). “The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking”. Journal of Clinical Psychopharmacology. 26 (6): 610–625. doi:10.1097/01.jcp.0000245566.52401.20. PMID 17110818. S2CID 35171287.
  52. ^ Jump up to:a b c d e Unterwald EM (September 2008). “Naltrexone in the treatment of alcohol dependence”. Journal of Addiction Medicine. 2 (3): 121–127. doi:10.1097/ADM.0b013e318182b20f. PMID 21768981. S2CID 23603792.
  53. ^ Jump up to:a b Rounsaville BJ (1995). “Can psychotherapy rescue naltrexone treatment of opioid addiction?” (PDF). NIDA Research Monograph. 150: 37–52. PMID 8742771. Archived (PDF) from the original on 19 January 2022. Retrieved 31 October 2021.
  54. ^ Carroll KM, Nich C, Frankforter TL, Yip SW, Kiluk BD, DeVito EE, Sofuoglu M (November 2018). “Accounting for the uncounted: Physical and affective distress in individuals dropping out of oral naltrexone treatment for opioid use disorder”. Drug and Alcohol Dependence. 192: 264–270. doi:10.1016/j.drugalcdep.2018.08.019. PMC 6203294. PMID 30300800.
  55. ^ Inagaki TK, Hazlett LI, Andreescu C (April 2020). “Opioids and social bonding: Effect of naltrexone on feelings of social connection and ventral striatum activity to close others”. Journal of Experimental Psychology. General. 149 (4): 732–745. doi:10.1037/xge0000674. PMC 7021584. PMID 31414860.
  56. ^ Inagaki TK, Hazlett LI, Andreescu C (May 2019). “Naltrexone alters responses to social and physical warmth: implications for social bonding”. Social Cognitive and Affective Neuroscience. 14 (5): 471–479. doi:10.1093/scan/nsz026. PMC 6545530. PMID 30976797.
  57. ^ Inagaki TK, Ray LA, Irwin MR, Way BM, Eisenberger NI (May 2016). “Opioids and social bonding: naltrexone reduces feelings of social connection”. Social Cognitive and Affective Neuroscience. 11 (5): 728–735. doi:10.1093/scan/nsw006. PMC 4847702. PMID 26796966.
  58. ^ Meier IM, Bos PA, Hamilton K, Stein DJ, van Honk J, Malcolm-Smith S (December 2016). “Naltrexone increases negatively-valenced facial responses to happy faces in female participants”. Psychoneuroendocrinology. 74: 65–68. doi:10.1016/j.psyneuen.2016.08.022. PMID 27588701. S2CID 40097592.
  59. ^ O’Brien CP, Gastfriend DR, Forman RF, Schweizer E, Pettinati HM (2011). “Long-term opioid blockade and hedonic response: preliminary data from two open-label extension studies with extended-release naltrexone”. The American Journal on Addictions. 20 (2): 106–112. doi:10.1111/j.1521-0391.2010.00107.x. PMC 3895092. PMID 21314752.
  60. ^ Mallik A, Chanda ML, Levitin DJ (February 2017). “Anhedonia to music and mu-opioids: Evidence from the administration of naltrexone”. Scientific Reports. 7: 41952. Bibcode:2017NatSR…741952M. doi:10.1038/srep41952. PMC 5296903. PMID 28176798.
  61. ^ Laeng B, Garvija L, Løseth G, Eikemo M, Ernst G, Leknes S (April 2021). “‘Defrosting’ music chills with naltrexone: The role of endogenous opioids for the intensity of musical pleasure”. Consciousness and Cognition. 90: 103105. doi:10.1016/j.concog.2021.103105. PMID 33711654. S2CID 232163311.
  62. ^ Jump up to:a b c d Ray LA, Chin PF, Miotto K (March 2010). “Naltrexone for the treatment of alcoholism: clinical findings, mechanisms of action, and pharmacogenetics”. CNS & Neurological Disorders Drug Targets. 9 (1): 13–22. doi:10.2174/187152710790966704. PMID 20201811.
  63. ^ Pfohl DN, Allen JI, Atkinson RL, Knopman DS, Malcolm RJ, Mitchell JE, Morley JE (1986). “Naltrexone hydrochloride (Trexan): a review of serum transaminase elevations at high dosage”. NIDA Research Monograph. 67: 66–72. PMID 3092099. Archived from the original on 21 January 2017. Retrieved 23 January 2017.
  64. ^ Reece AS (September 2010). “Clinical safety of 1500 mg oral naltrexone overdose”. BMJ Case Reports. 2010: bcr0420102871. doi:10.1136/bcr.04.2010.2871. PMC 3028212. PMID 22778191.
  65. ^ Pettinati HM, Dundon WD, Casares López MJ (2013). “Naltrexone and Opioid Antagonists for Alcohol Dependence”. In Miller PM (ed.). Interventions for Addiction. Elsevier. pp. 375–384. doi:10.1016/B978-0-12-398338-1.00039-7. ISBN 978-0-12-398338-1.
  66. ^ Raynor K, Kong H, Chen Y, Yasuda K, Yu L, Bell GI, Reisine T (February 1994). “Pharmacological characterization of the cloned κ-, δ-, and μ-opioid receptors”. Molecular Pharmacology. 45 (2): 330–334. CiteSeerX 10.1.1.1076.4629. PMID 8114680. INIST:3935705. Archived from the original on 22 June 2018. Retrieved 22 June 2018.
  67. ^ Codd EE, Shank RP, Schupsky JJ, Raffa RB (September 1995). “Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception”. The Journal of Pharmacology and Experimental Therapeutics. 274 (3): 1263–1270. PMID 7562497. Archived from the original on 2 February 2017. Retrieved 23 January 2017.
  68. ^ Toll L, Berzetei-Gurske IP, Polgar WE, Brandt SR, Adapa ID, Rodriguez L, et al. (March 1998). “Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications”. NIDA Research Monograph. 178: 440–466. CiteSeerX 10.1.1.475.3403. PMID 9686407.
  69. ^ Jump up to:a b Clark SD, Abi-Dargham A (October 2019). “The Role of Dynorphin and the Kappa Opioid Receptor in the Symptomatology of Schizophrenia: A Review of the Evidence”. Biological Psychiatry. 86 (7): 502–511. doi:10.1016/j.biopsych.2019.05.012. PMID 31376930. S2CID 162168648.
  70. ^ Peng X, Knapp BI, Bidlack JM, Neumeyer JL (May 2007). “Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors”. Journal of Medicinal Chemistry. 50 (9): 2254–2258. doi:10.1021/jm061327z. PMC 3357624. PMID 17407276.
  71. ^ Zheng MQ, Nabulsi N, Kim SJ, Tomasi G, Lin SF, Mitch C, et al. (March 2013). “Synthesis and evaluation of 11C-LY2795050 as a κ-opioid receptor antagonist radiotracer for PET imaging”. Journal of Nuclear Medicine. 54 (3): 455–463. doi:10.2967/jnumed.112.109512. PMC 3775344. PMID 23353688.
  72. ^ Cumming P, Marton J, Lilius TO, Olberg DE, Rominger A (November 2019). “A Survey of Molecular Imaging of Opioid Receptors”. Molecules. 24 (22): 4190. doi:10.3390/molecules24224190. PMC 6891617. PMID 31752279.
  73. ^ Wentland MP, Lu Q, Lou R, Bu Y, Knapp BI, Bidlack JM (April 2005). “Synthesis and opioid receptor binding properties of a highly potent 4-hydroxy analogue of naltrexone”. Bioorganic & Medicinal Chemistry Letters. 15 (8): 2107–2110. doi:10.1016/j.bmcl.2005.02.032. PMID 15808478.
  74. ^ Jump up to:a b Wentland MP, Lou R, Lu Q, Bu Y, Denhardt C, Jin J, et al. (April 2009). “Syntheses of novel high affinity ligands for opioid receptors”. Bioorganic & Medicinal Chemistry Letters. 19 (8): 2289–2294. doi:10.1016/j.bmcl.2009.02.078. PMC 2791460. PMID 19282177.
  75. ^ Jump up to:a b Dwoskin LP, ed. (29 January 2014). Emerging Targets and Therapeutics in the Treatment of Psychostimulant Abuse. Academic Press. pp. 398–. ISBN 978-0-12-420177-4. OCLC 1235841274. Archived from the original on 27 April 2021. Retrieved 30 October 2021.
  76. ^ Jump up to:a b Niciu MJ, Arias AJ (October 2013). “Targeted opioid receptor antagonists in the treatment of alcohol use disorders”. CNS Drugs. 27 (10): 777–787. doi:10.1007/s40263-013-0096-4. PMC 4600601. PMID 23881605.
  77. ^ Jump up to:a b c d e f g Wang D, Sun X, Sadee W (May 2007). “Different effects of opioid antagonists on mu-, delta-, and kappa-opioid receptors with and without agonist pretreatment”. The Journal of Pharmacology and Experimental Therapeutics. 321 (2): 544–552. doi:10.1124/jpet.106.118810. PMID 17267582. S2CID 28500012.
  78. ^ Jump up to:a b c Sadée W, Wang D, Bilsky EJ (February 2005). “Basal opioid receptor activity, neutral antagonists, and therapeutic opportunities”. Life Sciences. 76 (13): 1427–1437. doi:10.1016/j.lfs.2004.10.024. PMID 15680308.
  79. ^ Jump up to:a b c de Laat B, Nabulsi N, Huang Y, O’Malley SS, Froehlich JC, Morris ED, Krishnan-Sarin S (September 2021). “Occupancy of the kappa opioid receptor by naltrexone predicts reduction in drinking and craving”. Molecular Psychiatry. 26 (9): 5053–5060. doi:10.1038/s41380-020-0811-8. PMID 32541931. S2CID 219692020.
  80. ^ Placzek MS (August 2021). “Imaging Kappa Opioid Receptors in the Living Brain with Positron Emission Tomography”. Handbook of Experimental Pharmacology. 271: 547–577. doi:10.1007/164_2021_498. ISBN 978-3-030-89073-5. PMID 34363128. S2CID 236947969.
  81. ^ Vijay A, Morris E, Goldberg A, Petrulli J, Liu H, Huang Y, Krishnan-Sarin S (1 April 2017). “Naltrexone occupancy at kappa opioid receptors investigated in alcoholics by PET occupancy at kappa opioid receptors investigated in alcoholics by PET”. Journal of Nuclear Medicine. 58 (Supplement 1): 1297. Archived from the original on 29 October 2021. Retrieved 29 October 2021.
  82. ^ Waarde AV, Absalom AR, Visser AK, Dierckx RA (30 September 2020). “Positron Emission Tomography (PET) Imaging of Opioid Receptors” (PDF). In Dierckx RA, Otte A, de Vries EF, van Waarde A, Lammertsma AA (eds.). PET and SPECT of Neurobiological Systems. Springer International Publishing. pp. 749–807. doi:10.1007/978-3-030-53176-8_21. ISBN 978-3-030-53175-1. S2CID 241535315.
  83. ^ Jump up to:a b Soyka M, Rösner S (November 2010). “Nalmefene for treatment of alcohol dependence”. Expert Opinion on Investigational Drugs. 19 (11): 1451–1459. doi:10.1517/13543784.2010.522990. PMID 20868291. S2CID 9227860.
  84. ^ Jump up to:a b Mannelli P, Peindl KS, Wu LT (June 2011). “Pharmacological enhancement of naltrexone treatment for opioid dependence: a review”. Substance Abuse and Rehabilitation. 2011 (2): 113–123. doi:10.2147/SAR.S15853. PMC 3128868. PMID 21731898.
  85. ^ Schuh KJ, Walsh SL, Stitzer ML (July 1999). “Onset, magnitude and duration of opioid blockade produced by buprenorphine and naltrexone in humans”. Psychopharmacology. 145 (2): 162–174. doi:10.1007/s002130051045. PMID 10463317. S2CID 5930936.
  86. ^ Narcotic Antagonists: Naltrexone Pharmacochemistry and Sustained-release Preparations. Department of Health and Human Services, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute on Drug Abuse, Division of Research. 1981. pp. 148–. Archived from the original on 2 June 2021. Retrieved 2 June 2021.
  87. ^ Ingman K, Hagelberg N, Aalto S, Någren K, Juhakoski A, Karhuvaara S, et al. (December 2005). “Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing”. Neuropsychopharmacology. 30 (12): 2245–2253. doi:10.1038/sj.npp.1300790. PMID 15956985. S2CID 2453226.
  88. ^ Maqueda AE, Valle M, Addy PH, Antonijoan RM, Puntes M, Coimbra J, et al. (July 2016). “Naltrexone but Not Ketanserin Antagonizes the Subjective, Cardiovascular, and Neuroendocrine Effects of Salvinorin-A in Humans”. The International Journal of Neuropsychopharmacology. 19 (7): pyw016. doi:10.1093/ijnp/pyw016. PMC 4966277. PMID 26874330.
  89. ^ Walsh SL, Chausmer AE, Strain EC, Bigelow GE (January 2008). “Evaluation of the mu and kappa opioid actions of butorphanol in humans through differential naltrexone blockade”. Psychopharmacology. 196 (1): 143–155. doi:10.1007/s00213-007-0948-z. PMC 2766188. PMID 17909753.
  90. ^ Preston KL, Bigelow GE (February 1993). “Differential naltrexone antagonism of hydromorphone and pentazocine effects in human volunteers”. The Journal of Pharmacology and Experimental Therapeutics. 264 (2): 813–823. PMID 7679737.
  91. ^ Modesto-Lowe V, Van Kirk J (August 2002). “Clinical uses of naltrexone: a review of the evidence”. Experimental and Clinical Psychopharmacology. 10 (3): 213–227. doi:10.1037/1064-1297.10.3.213. PMID 12233982.
  92. ^ Lam L, Anand S, Li X, Tse ML, Zhao JX, Chan EW (April 2019). “Efficacy and safety of naltrexone for amfetamine and methamfetamine use disorder: a systematic review of randomized controlled trials”. Clinical Toxicology. 57 (4): 225–233. doi:10.1080/15563650.2018.1529317. PMID 30451013. S2CID 53951406.
  93. ^ Soyka M, Friede M, Schnitker J (March 2016). “Comparing Nalmefene and Naltrexone in Alcohol Dependence: Are there any Differences? Results from an Indirect Meta-Analysis”. Pharmacopsychiatry. 49 (2): 66–75. doi:10.1055/s-0035-1565184. PMID 26845589. S2CID 11540631.
  94. ^ Koob GF, Volkow ND (August 2016). “Neurobiology of addiction: a neurocircuitry analysis”. The Lancet. Psychiatry. 3 (8): 760–773. doi:10.1016/S2215-0366(16)00104-8. PMC 6135092. PMID 27475769.
  95. ^ Jump up to:a b c Toljan K, Vrooman B (September 2018). “Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization”. Medical Sciences. 6 (4): 82. doi:10.3390/medsci6040082. PMC 6313374. PMID 30248938.
  96. ^ Bachtell R, Hutchinson MR, Wang X, Rice KC, Maier SF, Watkins LR (2015). “Targeting the Toll of Drug Abuse: The Translational Potential of Toll-Like Receptor 4”. CNS & Neurological Disorders Drug Targets. 14 (6): 692–699. doi:10.2174/1871527314666150529132503. PMC 5548122. PMID 26022268.
  97. ^ Jump up to:a b Lee B, Elston DM (June 2019). “The uses of naltrexone in dermatologic conditions”. Journal of the American Academy of Dermatology. 80 (6): 1746–1752. doi:10.1016/j.jaad.2018.12.031. PMID 30582992. S2CID 58595160.
  98. ^ Zagon IS, Verderame MF, McLaughlin PJ (February 2002). “The biology of the opioid growth factor receptor (OGFr)”. Brain Research. Brain Research Reviews. 38 (3): 351–376. doi:10.1016/s0165-0173(01)00160-6. PMID 11890982. S2CID 37812525.
  99. ^ Dean RL (January 2005). “The preclinical development of Medisorb Naltrexone, a once a month long acting injection, for the treatment of alcohol dependence”. Frontiers in Bioscience. 10 (1–3): 643–655. doi:10.2741/1559. PMID 15569605.
  100. ^ Goonoo N, Bhaw-Luximon A, Ujoodha R, Jhugroo A, Hulse GK, Jhurry D (June 2014). “Naltrexone: a review of existing sustained drug delivery systems and emerging nano-based systems”. Journal of Controlled Release. 183: 154–166. doi:10.1016/j.jconrel.2014.03.046. PMID 24704710.
  101. ^ Jump up to:a b Dunbar JL, Turncliff RZ, Dong Q, Silverman BL, Ehrich EW, Lasseter KC (March 2006). “Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone”. Alcoholism, Clinical and Experimental Research. 30 (3): 480–490. doi:10.1111/j.1530-0277.2006.00052.x. PMID 16499489.
  102. ^ Swainston Harrison T, Plosker GL, Keam SJ (2006). “Extended-release intramuscular naltrexone”. Drugs. 66 (13): 1741–1751. doi:10.2165/00003495-200666130-00006. PMID 16978037. S2CID 21309382.
  103. ^ Mannelli P, Peindl K, Masand PS, Patkar AA (October 2007). “Long-acting injectable naltrexone for the treatment of alcohol dependence”. Expert Review of Neurotherapeutics. 7 (10): 1265–1277. doi:10.1586/14737175.7.10.1265. PMID 17939765. S2CID 36453900.
  104. ^ “Vivitrol (naltrexone for extended-release injectable suspension)”. ALK-VIV. 28 November 2018. Archived from the original on 31 October 2021. Retrieved 31 October 2021.
  105. ^ Davis MP, Glare PA, Hardy J (28 May 2009). Opioids in Cancer Pain. Oxford University Press. pp. 41–. ISBN 978-0-19-923664-0. Archived from the original on 31 October 2021. Retrieved 31 October 2021.
  106. ^ Jump up to:a b c Hipkin RW, Dolle RE (2010). Opioid Receptor Antagonists for Gastrointestinal Dysfunction. Annual Reports in Medicinal Chemistry. Vol. 45. pp. 142–155. doi:10.1016/S0065-7743(10)45009-5. ISBN 978-0-12-380902-5.
  107. ^ Ray LA, Barr CS, Blendy JA, Oslin D, Goldman D, Anton RF (March 2012). “The role of the Asn40Asp polymorphism of the mu opioid receptor gene (OPRM1) on alcoholism etiology and treatment: a critical review”. Alcoholism, Clinical and Experimental Research. 36 (3): 385–394. doi:10.1111/j.1530-0277.2011.01633.x. PMC 3249007. PMID 21895723.
  108. ^ Garbutt JC, Greenblatt AM, West SL, Morgan LC, Kampov-Polevoy A, Jordan HS, Bobashev GV (August 2014). “Clinical and biological moderators of response to naltrexone in alcohol dependence: a systematic review of the evidence”. Addiction. 109 (8): 1274–1284. doi:10.1111/add.12557. PMID 24661324.
  109. ^ Jump up to:a b National Research Council (U.S.). Committee on Problems of Drug Dependence (1974). Report of the Thirty-sixth Annual Scientific Meeting: Committee on Problems of Drug Dependence, Mexico City, March 10-14, 1974. National Academies. pp. 265–. ISBN 9780309022446. NAP:13963. Archived from the original on 27 April 2021. Retrieved 4 December 2017.
  110. ^ Padwa HM, Cunningham J (2010). Addiction: A Reference Encyclopedia. ABC-CLIO. pp. 207–. ISBN 978-1-59884-229-6.
  111. ^ Bennett G (14 January 2004). Treating Drug Abusers. Routledge. pp. 112–. ISBN 978-1-134-93173-6. Archived from the original on 27 April 2021. Retrieved 4 December 2017.
  112. ^ Jump up to:a b c Wouk J (1 March 2009). Google Ldn !. Lulu.com. pp. 78–88. ISBN 978-0-578-00439-6. Archived from the original on 28 April 2021. Retrieved 4 December 2017.
  113. ^ Jump up to:a b Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 851–. ISBN 978-1-4757-2085-3. Archived from the original on 6 August 2020. Retrieved 4 December 2017.
  114. ^ Jump up to:a b Index Nominum 2000: International Drug Directory. Taylor & Francis. 2000. pp. 715–. ISBN 978-3-88763-075-1. Archived from the original on 6 August 2020. Retrieved 4 December 2017.
  115. ^ Jump up to:a b Morton IK, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 189–. ISBN 978-94-011-4439-1.
  116. ^ Jump up to:a b c “Naltrexone”. Archived from the original on 4 December 2017. Retrieved 4 December 2017.
  117. ^ “Bupropion and naltrexone Uses, Side Effects & Warnings”. Drugs.com. 8 June 2020. Archived from the original on 26 October 2020. Retrieved 16 September 2020.
  118. ^ “Morphine and naltrexone Uses, Side Effects & Warnings”. Drugs.com. 14 October 2019. Archived from the original on 25 October 2020. Retrieved 16 September 2020.
  119. ^ McCann DJ (April 2008). “Potential of buprenorphine/naltrexone in treating polydrug addiction and co-occurring psychiatric disorders”. Clinical Pharmacology and Therapeutics. 83 (4): 627–630. doi:10.1038/sj.clpt.6100503. PMID 18212797. S2CID 21165673.
  120. ^ Armstrong W (7 May 2013). “A Shot in the Dark: Can Vivitrol Help Us Control Our Addictions?”. Pacific Standard. Archived from the original on 13 September 2017.
  121. ^ Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL (April 2011). “Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial”. Lancet. 377 (9776): 1506–1513. doi:10.1016/s0140-6736(11)60358-9. PMID 21529928. S2CID 16690413.
  122. ^ Wolfe D, Carrieri MP, Dasgupta N, Bruce D, Wodak A (2011). “Injectable extended-release naltrexone for opioid dependence – Authors’ reply”. The Lancet. 378 (9792): 666. doi:10.1016/S0140-6736(11)61333-0. S2CID 205963967.
  123. ^ Tanum L, Solli KK, Latif ZE, Benth JŠ, Opheim A, Sharma-Haase K, et al. (December 2017). “Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial”. JAMA Psychiatry. 74 (12): 1197–1205. doi:10.1001/jamapsychiatry.2017.3206. PMC 6583381. PMID 29049469.
  124. ^ Jump up to:a b c Goodnough A, Zernike K (11 June 2017). “Seizing on Opioid Crisis, a Drug Maker Lobbies Hard for Its Product”. The New York Times. Archived from the original on 11 June 2017. Retrieved 11 June 2017. Advertising for Vivitrol on a subway car in Brooklyn last month. Marketing for the drug has shifted into high gear.
  125. ^ MacGillis A. “The Last Shot”. ProPublica. Archived from the original on 28 December 2021. Retrieved 29 December 2021.
  126. ^ Wolfe D, Saucier R (February 2021). “Biotechnologies and the future of opioid addiction treatments”. The International Journal on Drug Policy. 88: 103041. doi:10.1016/j.drugpo.2020.103041. PMID 33246267. S2CID 227191111.
  127. ^ Harper J (7 November 2017). “Kamala Harris Investigating Addiction Drug Manufacturer Alkermes”. WFYI Public Media. Archived from the original on 14 June 2022. Retrieved 29 December 2021.
  128. ^ Office of the FDA Commissioner (24 March 2020). “FDA issues warning letter for not including the most serious risks in advertisement for medication-assisted treatment drug”. Food and Drug Administration. Archived from the original on 29 December 2021. Retrieved 29 December 2021.
  129. ^ Jump up to:a b “Letter to Tom Price”. May 2017. Archived from the original on 25 June 2017. Retrieved 11 June 2017.
  130. ^ One Little Pill (2014) at IMDb
  131. ^ Jump up to:a b c d Simeon D, Abugel J (10 October 2008). Feeling Unreal: Depersonalization Disorder and the Loss of the Self. Oxford University Press. pp. 166–. ISBN 978-0-19-976635-2. Archived from the original on 15 February 2017. Retrieved 4 October 2016.
  132. ^ Jump up to:a b c d Lanius UF, Paulsen SL, Corrigan FM (13 May 2014). Neurobiology and Treatment of Traumatic Dissociation: Towards an Embodied Self. Springer Publishing Company. pp. 489–. ISBN 978-0-8261-0632-2. Archived from the original on 15 February 2017. Retrieved 4 October 2016.
  133. ^ Sierra M (January 2008). “Depersonalization disorder: pharmacological approaches”. Expert Review of Neurotherapeutics. 8 (1): 19–26. doi:10.1586/14737175.8.1.19. PMID 18088198. S2CID 22180718.
  134. ^ Novella S (5 May 2010). “Low Dose Naltrexone – Bogus or Cutting Edge Science?”. Science-Based Medicine. Archived from the original on 8 July 2011. Retrieved 5 July 2011.
  135. ^ “Low-Dose Naltrexone”. National MS Society. Archived from the original on 13 May 2014. Retrieved 12 May 2014.
  136. ^ Novella S (5 May 2010). “Low Dose Naltrexone – Bogus or Cutting Edge Science?”. Archived from the original on 8 July 2011. Retrieved 5 July 2011.
  137. ^ Bowling AC. “Low-dose naltrexone (LDN) The “411” on LDN”. National Multiple Sclerosis Society. Archived from the original on 29 September 2009. Retrieved 6 July 2011.
  138. ^ Steenhuysen J (18 October 2022). “Addiction drug shows promise lifting long COVID brain fog, fatigue”. Reuters.
  139. ^ Smith SG, Gupta KK, Smith SH (1995). “Effects of naltrexone on self-injury, stereotypy, and social behavior of adults with developmental disabilities”. Journal of Developmental and Physical Disabilities. 7 (2): 137–46. doi:10.1007/BF02684958. S2CID 144215400.
  140. ^ Manley C (20 March 1998). “Self-injuries may have biochemical base: study”. The Reporter. Archived from the original on 5 January 2009.
  141. ^ Grant JE, Kim SW, Odlaug BL (April 2009). “A double-blind, placebo-controlled study of the opiate antagonist, naltrexone, in the treatment of kleptomania”. Biological Psychiatry. 65 (7): 600–606. doi:10.1016/j.biopsych.2008.11.022. PMID19217077. S2CID22992128.
  142. ^ Clinical trial number NCT00326807 for “A Randomized, Double-Blind, Placebo-Controlled Trial of Naltrexone in the Treatment of Concurrent Alcohol Dependence and Pathological Gambling” at ClinicalTrials.gov
  143. ^ Kim SW, Grant JE, Adson DE, Shin YC (June 2001). “Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling”. Biological Psychiatry. 49 (11): 914–921. doi:10.1016/S0006-3223(01)01079-4. PMID 11377409. S2CID 22134798.
  144. ^ Bostwick JM, Bucci JA (February 2008). “Internet sex addiction treated with naltrexone”. Mayo Clinic Proceedings. 83 (2): 226–230. doi:10.4065/83.2.226. PMID 18241634.
  145. ^ Vignau J, Karila L, Costisella O, Canva V (2005). “[Hepatitis C, interferon a and depression: main physiopathologic hypothesis]” [Hepatitis C, interferon a and depression: main physiopathologic hypothesis]. L’Encéphale (in French). 31 (3): 349–357. doi:10.1016/s0013-7006(05)82400-5. PMID 16142050. INIST:16920336.
  146. ^ Małyszczak K, Inglot M, Pawłowski T, Czarnecki M, Rymer W, Kiejna A (2006). “[Neuropsychiatric symptoms related to interferon alpha]” [Neuropsychiatric symptoms related to interferon alpha]. Psychiatria Polska (in Polish). 40 (4): 787–797. PMID 17068950. Archived from the original on 2 February 2017.
  147. ^ Campbell ND (28 March 2013). “Why Can’t They Stop?” A Highly Public Misunderstanding of Science. pp. 238–262. doi:10.1215/9780822395874-010. ISBN 978-0-8223-5350-8. Archived from the original on 14 June 2022. Retrieved 20 December 2020.
  148. ^ Vrecko S (1 June 2009). “Therapeutic Justice in Drug Courts: Crime, Punishment and Societies of Control”. Science as Culture. 18 (2): 217–232. doi:10.1080/09505430902885623. S2CID 144197523.
  149. ^ Aleksanyan J (9 May 2020). “Governing beyond the closet: Remaking stigma, identity, and sexual behavior in a post-disciplinary rehab”. Ethnography. 23 (4): 516–538. doi:10.1177/1466138120923702. S2CID 218936388.
  150. ^ Malandain L, Blanc JV, Ferreri F, Thibaut F (May 2020). “Pharmacotherapy of Sexual Addiction” (PDF). Current Psychiatry Reports. 22 (6): 30. doi:10.1007/s11920-020-01153-4. PMID 32377953. S2CID 218527367.
  151. ^ Herron, Abigail J., Brennan, Tim K. eds. ASAM Essentials of Addiction Medicine, The. 3rd Edition. Two Commerce Square, 2001 Market Street, Philadelphia, PA 19103 USA:Lippincott Williams & Wilkins; 2020.[page needed]

Related Posts

Trending now

Propecia
Cytotec
Amoxicillin
Levitra